Patents by Inventor Faith NATHAN

Faith NATHAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENT OF LUNG CANCER USING A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND AN ANTI-CTLA-4 ANTIBODY
    Publication number: 20220017619
    Abstract: This disclosure provides a method for treating a subject afflicted with a lung cancer, which method comprises administering to the subject therapeutically effective amounts of: (a) an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity; and (b) an antibody or an antigen-binding portion thereof that specifically binds to a Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) and inhibits CTLA-4 activity.
    Type: Application
    Filed: July 26, 2021
    Publication date: January 20, 2022
    Applicant: Bristol-Myers Squibb Company
    Inventor: Faith Nathan
  • Treatment of lung cancer using a combination of an anti-PD-1 antibody and an anti-CTLA-4 antibody
    Patent number: 11072657
    Abstract: This disclosure provides a method for treating a subject afflicted with a lung cancer, which method comprises administering to the subject therapeutically effective amounts of: (a) an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity; and (b) an antibody or an antigen-binding portion thereof that specifically binds to a Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) and inhibits CTLA-4 activity.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: July 27, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventor: Faith Nathan
  • TREATMENT OF LUNG CANCER USING A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND ANOTHER ANTI-CANCER AGENT
    Publication number: 20210206854
    Abstract: This disclosure provides a method for treating a subject afflicted with a lung cancer, which method comprises administering to the subject therapeutically effective amounts of: (a) an anticancer agent which is an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity which can be administered by infusion for less than 60 minutes; and, optionally, (b) another anti-cancer agent which is administered by infusion for less than 90 minutes. The other anti-cancer agent can be an anti-Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) antibody.
    Type: Application
    Filed: January 27, 2017
    Publication date: July 8, 2021
    Applicant: Bristol-Myers Squibb Company
    Inventor: Faith NATHAN
  • TREATMENT OF LUNG CANCER USING A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND AN ANTI-CTLA-4 ANTIBODY
    Publication number: 20180371092
    Abstract: This disclosure provides a method for treating a subject afflicted with a lung cancer, which method comprises administering to the subject therapeutically effective amounts of: (a) an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity; and (b) an antibody or an antigen-binding portion thereof that specifically binds to a Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) and inhibits CTLA-4 activity.
    Type: Application
    Filed: November 18, 2016
    Publication date: December 27, 2018
    Applicant: Bristol-Myers Squibb Company
    Inventor: Faith NATHAN